PBSC Transplantation in patients receiving ablative doses of 186Re HEDP for skeletal secondaries from prostate cancer

被引：0
|
作者：
McCready, R
Treleaven, J
Al Deen, A
Dearnaley, D
Powles, R
机构：
[1] Royal Marsden Hosp, NHS Trust, Dept Nucl Med, Sutton, Surrey, England
[2] Royal Marsden Hosp, NHS Trust, Dept Haematol, Sutton, Surrey, England
来源：
BONE MARROW TRANSPLANTATION | 1998年 / 21卷
关键词：
D O I：
暂无
中图分类号：
Q6 [生物物理学];
学科分类号：
071011 ;
摘要：
795
引用
收藏
页码：S227 / S227
页数：1
相关论文
共 20 条
  • [1] Prediction of response of skeletal metastases from cancer of the prostate to high activity 186Re HEDP therapy.
    McCready, VR
    O'Sullivan, J
    Dearnaley, D
    Cook, G
    JOURNAL OF NUCLEAR MEDICINE, 2002, 43 (05) : 316P - 316P
  • [2] Unexpected hematological tolerance to high activity 186Re HEDP therapy for skeletal metastases in prostate carcinoma.
    McCready, VR
    O'Sullivan, J
    Norman, A
    Dearnaley, DP
    Treleaven, JG
    Binnie, D
    JOURNAL OF NUCLEAR MEDICINE, 2001, 42 (05) : 313P - 313P
  • [3] [186Re]-HEDP in the palliation of painful bone metastases from cancers other than prostate and breast
    Minutoli, F.
    Herberg, A.
    Spadaro, P.
    Pecorella, G. Restifo
    Baldari, S.
    Arico, D.
    Altavilla, G.
    Baldari, S.
    QUARTERLY JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2006, 50 (04): : 355 - 362
  • [4] Comparison of PSA measurements and scintigraphy in patients with skeletal metastases from carcinoma of the prostate treated with high activities of Re 186 HEDP.
    McCready, VR
    O'Sullivan, JM
    Dearnaley, DP
    Treleaven, J
    Cook, G
    JOURNAL OF NUCLEAR MEDICINE, 2003, 44 (05) : 412P - 413P
  • [5] Metastatic control probability in patients with prostate cancer metastatic to bone treated 186Re-HEDP
    Denis-Bacelar, A. M.
    Divoli, A.
    Chittenden, S.
    Du, Y.
    Flux, G. D.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2015, 42 : S58 - S58
  • [6] Absorbed dose distributions in patients with bone metastases from hormone refractory prostate cancer treated with Re-186 HEDP
    Bacelar, A. M. Denis
    Divoli, A.
    Chittenden, S.
    Du, Y.
    Dearnaley, D. P.
    O'Sullivan, J. M.
    Flux, G. D.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2013, 40 : S188 - S188
  • [7] Retrospective dosimetry in palliative molecular radiotherapy with 186Re-HEDP for bone pain in patients with castrate-resistant prostate cancer
    Denis-Bacelar, A. M.
    Divoli, A.
    Chittenden, S.
    Du, Y.
    Dearnaley, D. P.
    O'Sullivan, J. M.
    Frisch, K. J.
    Flux, G. D.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2014, 41 : S174 - S175
  • [8] A model-based method for the prediction of whole-body absorbed dose and bone marrow toxicity for 186Re-HEDP treatment of skeletal metastases from prostate cancer
    Francesca M. Buffa
    Glenn D. Flux
    Matt J. Guy
    Joe M. O'Sullivan
    Victor R. McCready
    Sarah J. Chittenden
    David P. Dearnaley
    European Journal of Nuclear Medicine and Molecular Imaging, 2003, 30 : 1114 - 1124
  • [9] A model-based method for the prediction of whole-body absorbed dose and bone marrow toxicity for 186Re-HEDP treatment of skeletal metastases from prostate cancer
    Buffa, FM
    Flux, GD
    Guy, MJ
    O'Sullivan, JM
    McCready, VR
    Chittenden, SJ
    Dearnaley, DP
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2003, 30 (08) : 1114 - 1124
  • [10] The optimum method to determine the maximum tolerated activity for high activity Re186HEDP therapy with peripheral blood stem cell support for skeletal metastases from prostate cancer
    McCready, VR
    O'Sullivan, J
    Norman, A
    Treleaven, J
    Dearnaley, D
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2004, 31 : S480 - S481
12